Business Context and Reporting Period
Company: NanoViricides, Inc. (NNVC)
Filing Type: Form 10-Q (Unaudited)
Period Ended: December 31, 2012
Business Stage: Development Stage Company
Overview: NanoViricides is a nano-biopharmaceutical company focused on discovering and developing therapeutics for life-threatening viral infections. The company holds exclusive, perpetual licenses from TheraCour Pharma, Inc. for its nanoviricide technology. As of the reporting date, the company has no commercialized products and generates no revenue. Operations are funded through equity and debt financing.
Key Financial Metrics
| Metric | Six Months Ended Dec 31, 2012 | Six Months Ended Dec 31, 2011 |
|---|---|---|
| Revenue | $0 | $0 |
| Net Loss | $(3,012,340) | $(2,531,295) |
| Operating Expenses | $2,837,244 | $2,457,715 |
| Cash and Cash Equivalents (Ending) | $13,879,872 | $12,099,083 |
| Total Assets | $15,612,284 | $15,629,808 |
| Total Liabilities | $1,397,418 | $1,779,615 |
| Stockholders' Equity | $14,214,866 | $13,850,193 |
| Accumulated Deficit | $(32,436,456) | $(29,424,116) |
Debt and Liquidity: The company reported no long-term debt as of December 31, 2012. Current liabilities totaled $1,397,418, primarily consisting of accounts payable to related parties ($666,884) and a derivative liability ($372,733). The company maintains a strong liquidity position with approximately $13.9 million in cash.
Material Changes vs. Prior Period
- Net Loss Increase: Net loss increased by approximately $481,000 (19%) compared to the prior six-month period, driven by higher operating expenses.
- Operating Expenses: Total operating expenses rose to $2.84 million from $2.46 million. Research and Development (R&D) expenses increased to $1.92 million from $1.67 million, while General and Administrative (G&A) expenses rose to $917,000 from $788,000.
- Derivative Liability: The derivative liability decreased significantly from $1,078,698 to $372,733, resulting in a non-cash gain of $226,549 included in other income/expense.
- Financing Activity: The company raised $2,322,500 in net proceeds from the issuance of Series C Convertible Preferred Stock during the six-month period.
Guidance, Outlook, and Risks
Management Commentary and Outlook: Management believes the company has sufficient capital to fund operations through at least December 31, 2014, based on current expenditure rates and a subsequent $6 million debenture offering in February 2013. The company is advancing its drug pipeline, specifically the "FluCide" anti-influenza candidate (NV-INF-1), for which it held a pre-IND meeting with the FDA in March 2012. Significant progress was reported in August 2012 regarding an orally effective anti-influenza drug candidate. The company is also developing a cGMP manufacturing facility in Shelton, CT, via a related party (Inno-Haven, LLC).
Risks and Contingencies:
- Going Concern: While currently funded, the company has incurred significant losses since inception and expects recurring losses until product commercialization. There is no assurance of future profitability.
- Legal Proceedings: A shareholder derivative lawsuit (Yidam, Ltd. v. Eugene Seymour, Anil Diwan, and Nanoviricides, Inc.) is ongoing. While most claims were dismissed, a dispute remains regarding the inspection of the shareholder list. No monetary damages are expected.
- Related Party Transactions: The company relies heavily on TheraCour Pharma, Inc. (controlled by the President/Chairman) for technology licensing and manufacturing. Significant prepaid expenses and accounts payable are owed to related parties.
- Regulatory Risk: Success depends on obtaining FDA approval for IND applications and subsequent clinical trials, which are subject to significant uncertainty.
Investor Verification Checklist
- Cash Runway: Verify the sufficiency of the $13.9 million cash balance against the projected $10 million additional funding requirement for IND filing and clinical trials.
- Related Party Dependence: Review the terms of the license agreement with TheraCour Pharma, Inc. and the proposed lease/collateral agreement with Inno-Haven, LLC (controlled by the CEO).
- Derivative Liability: Confirm the valuation methodology and potential future volatility of the remaining $372,733 derivative liability.
- Legal Status: Monitor the resolution of the shareholder derivative lawsuit regarding the shareholder list inspection.
- Subsequent Events: Review the terms of the $6 million Series B Convertible Debenture issued in February 2013, including conversion prices and interest share obligations.